Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders.

MLA

Hsiao, Shih-Hsin, et al. “Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase Inhibitors: Non-Responders versus Responders.” PloS One, vol. 8, no. 12, Dec. 2013, p. e83266. EBSCOhost, https://doi.org/10.1371/journal.pone.0083266.

APA

Hsiao, S.-H., Liu, H. E., Lee, H.-L., Lin, C.-L., Chen, W.-Y., Wu, Z.-H., Lin, S.-E., Chiang, L.-L., & Chung, C.-L. (2013). Distinct clinical outcomes of non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: non-responders versus responders. PloS One, 8(12), e83266. https://doi.org/10.1371/journal.pone.0083266

Chicago

Hsiao, Shih-Hsin, H Eugene Liu, Hsin-Lun Lee, Chii-Lan Lin, Wei-Yu Chen, Zhung-Han Wu, Sey-En Lin, Ling-Ling Chiang, and Chi-Li Chung. 2013. “Distinct Clinical Outcomes of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor (EGFR) Mutations Treated with EGFR Tyrosine Kinase Inhibitors: Non-Responders versus Responders.” PloS One 8 (12): e83266. doi:10.1371/journal.pone.0083266.